FGF23 and X-linked hypophosphatemia: Burosumab is indicated and recommended for the treatment of X-linked hypophosphatemic rickets (XLH), another disorder of FGF23 excess in children with radiographic evidence of rickets from 1 yr of age and in symptomatic adults.6